IMA203-301_SUPRAME (IMA203): A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of IMA203 Versus Investigator's Choice of Treatment in Patients With Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ACTengine® IMA203-301)

Objective

Clinical Trial Details

Principal Investigator(s)

Benjamin Solomon, MD

Clinical Trial Categories

• Cancer
• Melanoma

Contact

Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org